H.R. 3 would reduce drug prices for patients and payers
Estimated savings from negotiations for a 30-day supply of branded drugs
Note: The price for Acthar is for a three-week course of treatment for multiple sclerosis, and the price for insulin drugs are based on dosage for a typical patient.
Center for American Progress
Source:CAP analysis based on U.S. Centers for Medicare and Medicaid Services, "Medicare Part D Drug Spending Dashboard," available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartD (last accessed June 2021); Philip L. Swagel, "Re: Effects of Drug Price Negotiation Stemming From Title 1 of H.R. 3, the Lower Drug Costs Now Act of 2019, on Spending and Revenues Related to Part D of Medicare," Congressional Budget Office, October 11, 2019, available at https://www.cbo.gov/system/files/2019-10/hr3ltr.pdf. Additional data points that CAP used were provided by third-party researchers and are on file with authors: SSR Health (2021); AnalySource® as reprinted with permission by First DataBank Inc via Patients For Affordable Drugs (2021).